Jefferies Upgrades Integra Lifesciences to Buy, Lowers Price Target to $53
Portfolio Pulse from richadhand@benzinga.com
Jefferies analyst Matthew Taylor has upgraded Integra Lifesciences (NASDAQ:IART) from Hold to Buy, but lowered the price target from $58 to $53.
July 12, 2023 | 9:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Integra Lifesciences has been upgraded to Buy by Jefferies, but the price target has been lowered from $58 to $53.
The upgrade to Buy indicates a positive outlook for the company's stock. However, the lowering of the price target may temper the enthusiasm somewhat. Overall, this is likely to have a positive impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100